Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2023-12-20 Share Issue/Capital Cha…
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Share Issue/Capital Change Classification · 1% confidence The document is titled "ERRATUM RELATIF A LA REALISATION DE LA FUSION-ABSORPTION DE THERADIAG PAR BIOSYNEX" (Errata regarding the completion of the merger-absorption of THERADIAG by BIOSYNEX). It details a correction to the number of shares to be issued as consideration for the merger, which is a change in capital structure resulting from a corporate transaction (M&A/Financing). It also includes a forward-looking statement about the next publication (Annual Revenue 2023). Since the core content is about the finalization and correction of a share issuance related to a merger, it strongly relates to capital changes resulting from a transaction. The most fitting categories are 'Capital/Financing Update' (CAP) or 'M&A Activity' (TAR). Given the specific focus on the resulting share issuance correction (capital change), 'CAP' is highly relevant. However, since it is an erratum correcting the share exchange ratio following a merger, 'TAR' (M&A Activity) is also very strong. Since the document explicitly details the resulting capital increase ('augmentation de capital social'), 'CAP' is a very precise fit for the mechanics described. Alternatively, because it is a formal announcement correcting a prior step in a major corporate transaction (merger), it can also be classified as a general regulatory filing if a more specific M&A/Capital code isn't deemed perfect. Given the explicit mention of the share issuance correction, I will classify it as Capital/Financing Update (CAP), as the primary actionable information is the capital adjustment. It is not a simple announcement of a report (RPA) but the substance of the correction itself.
2023-12-20 French
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
AGM Information Classification · 1% confidence The document announces the completion of a merger (fusion-absorption) between THERADIAG and BIOSYNEX, effective on December 15, 2023. This transaction involves the issuance of new BIOSYNEX shares to THERADIAG shareholders and the suspension/delisting of THERADIAG shares. This is a significant corporate action related to capital structure and corporate control, but it is not a standard periodic financial report (10-K, IR, ER). It specifically details the exchange ratio, capital increase, and admission/suspension of trading. This type of announcement, detailing a merger or takeover proposal/completion, aligns best with the 'M&A Activity' category (TAR). Although it results in a capital change (SHA), the primary focus is the merger transaction itself.
2023-12-15 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Déclaration du nombre d'actions et des droits de vote au 30 novembre 2023" (Declaration of the number of shares and voting rights as of November 30, 2023). It explicitly cites the regulatory requirement under Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, which mandates the publication of the total number of shares and theoretical voting rights. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related statutory disclosures about voting power.
2023-12-07 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document explicitly announces 'Theradiag reports 20% revenue growth in Q3 2023' and provides detailed financial figures for the third quarter ending September 30, 2023. This content structure—summarizing key performance indicators (revenue, sales) for a specific, non-annual period (Q3)—is characteristic of an Earnings Release (ER). Although it contains some operational details, its primary function is the initial announcement of period results, not the comprehensive analysis found in an Interim Report (IR) or the full audited statements of a 10-K. The document length (under 5,000 characters) and its focus on immediate results support the ER classification over a comprehensive IR. 9M 2023
2023-10-11 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled with a headline announcing revenue growth for the third quarter of 2023 ("Theradiag affiche une croissance de son chiffre d'affaires de 20% au cours du 3ème trimestre 2023"). It provides detailed financial figures for Q3 2023 and the nine-month period ending September 30, 2023, including revenue breakdowns by business segment (Théranostic and IVD) and cash position. This content structure—presenting key financial metrics for a specific recent period (quarterly) immediately following the period end—is characteristic of an Earnings Release (ER). It is not a comprehensive annual report (10-K) or a full interim report (IR), as it focuses on the highlights and key figures rather than a full set of audited statements and extensive MD&A typically found in those documents. It is an initial announcement of results. 9M 2023
2023-10-11 French
Informations privilégiées / Autres communiqués
M&A Activity Classification · 1% confidence The document is a press release detailing the 'PROJET DE FUSION PAR ABSORPTION DE THERADIAG PAR BIOSYNEX' (Projected Merger by Absorption of THERADIAG by BIOSYNEX). This announcement concerns a significant corporate transaction involving the merger of two companies, including the exchange ratio (1 BIOSYNEX share for 7 THERADIAG shares) and the expected timeline for shareholder approval. This clearly falls under the category of corporate actions related to mergers, acquisitions, or takeovers. Based on the provided definitions, the most appropriate code is 'TAR' (M&A Activity). The document is a detailed announcement, not a short notice of publication, so RPA/RNS is less appropriate than the specific M&A code.
2023-09-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.